Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
Patent 5169933 Issued on December 8, 1992. Estimated Expiration Date: 
December 8, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
December 8, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesHybrid protein Radioimmunotoxins Radionuclide antibody coupling Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects Toxin conjugates Patent #: 4894443 InventorsAssigneeApplicationNo. 390241 filed on 08/07/1989US Classes:530/391.3, Conjugated to a detectable label or radioisotope or radionuclide or heavy metal-containing compound424/1.41, Attached to lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interferon, interleukin, macrophage factor, colony stimulating factor, erythropoietin); derivative thereof424/1.45, Attached to cyclopentano-hydrophenanthrene (e.g., cholesterol, bile acid, steroids, cholane), hormone, or neurotransmitter, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator (e.g., T3, T4, insulin, human chorionic gonadotropin, intragonadal regulatory protein, Mullerian inhibiting substance, inhibin, epidermal growth factor, nerve growth factor, dopamine, norepinephrine); derivative thereof424/1.53, Attachment via an added element (e.g., bifunctional compound or coordinate, coupling agent, spacer compound, bridging compound, conjugated chelate)424/1.69, Attached to peptide or protein of 2+ amino acid units (e.g., dipeptide, folate, fibrinogen, transferrin, sp. enzymes); derivative thereof424/9.1, IN VIVO DIAGNOSIS OR IN VIVO TESTING424/180.1, Conjugate includes potentiator or composition comprising conjugate includes potentiator530/306, Corticotropin (ATCH); related peptides530/307, Calcitonin; related peptides530/308, Glucagon; related peptides530/313, Lutenizing hormone releasing factor (LRF); related peptides530/323, Peptides with at least one nonpeptide bond other than a disulfide bond joining two or more sequences of amino acid residues, e.g., homomeric heterodectic peptide other than cyclic disulfide, depsipeptides, etc.530/324, 25 or more amino acid residues in defined sequence530/325, 24 amino acid residues in defined sequence530/326, 15 to 23 amino acid residues in defined sequence530/327, 11 to 14 amino acid residues in defined sequence530/328, 8 to 10 amino acid residues in defined sequence530/329, 6 to 7 amino acid residues in defined sequence530/330, 4 to 5 amino acid residues in defined sequence530/351, Lymphokines, e.g., interferons, interlukins, etc.530/377, Derived from oil seed, e.g., cotton seed, rapeseed, sunflower, etc.530/391.1, Monoclonal or polyclonal antibody or immunoglobulin or fragment thereof that is conjugated or adsorbed (e.g., adsorbed to a solid support, etc.)530/391.5, Conjugated via a specifically-identified linking group, chelating group, coordination complex, coupling agent, or conjugation agent530/391.7, Conjugated to a cytotoxic agent, drug, or other biologically-active substance530/391.9, Conjugated via a specifically-identified linking group, coupling agent, or conjugation agent530/395, Glycoprotein, e.g., mucins proteoglycans, etc.530/399, Hormones, e.g., prolactin, thymosin, growth factors, etc.530/403, Protein is identified as an antigen, e.g., immunogenic carriers, etc.530/408, Sulfur containing reactant530/409, Nitrogen containing reactant530/410Oxygen containing reactantExaminersPrimary: Nucker, Christine M.Assistant: Kim, Harry C. International ClassesC07K 017/02C07K 007/06 C07K 007/08 C07K 007/10 C07K 007/34 C07K 007/36 C07K 007/38 A61K 049/02 AbstractCovalently-linked complexes (CLCs) for targeting a defined population of cells, comprising a targeting protein; a cytotoxic agent; and an enhancing moiety, wherein the enhancing moiety is capable of promoting CLC-target cell interaction are disclosed. Methods for using the claimed CLCs to obtain enhanced in vivo cytotoxicity and enhanced in vivo imaging are also described.Other References
Field of SearchGlycoprotein, e.g., mucins proteoglycans, etc.25 or more amino acid residues in defined sequence 24 amino acid residues in defined sequence 15 to 23 amino acid residues in defined sequence 11 to 14 amino acid residues in defined sequence 8 to 10 amino acid residues in defined sequence 6 to 7 amino acid residues in defined sequence 4 to 5 amino acid residues in defined sequence Derived from oil seed, e.g., cotton seed, rapeseed, sunflower, etc. Hormones, e.g., prolactin, thymosin, growth factors, etc. Protein is identified as an antigen, e.g., immunogenic carriers, etc. Sulfur containing reactant Nitrogen containing reactant Stablizing an enzyme by forming a mixture, an adduct or a composition, or formation of an adduct or enzyme conjugate |
| ||||||||||||||
